STAR IN THE NEWS
June 26, 2024
SOUTH SAN FRANCISCO, CA, June 26, 2024 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...
Press Release
January 3, 2024
SOUTH SAN FRANCISCO, CA, January 3, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...
Press Release
January 2, 2024
SOUTH SAN FRANCISCO, CA, January 2, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...
Press Release
December 5, 2023
SOUTH SAN FRANCISCO, CA, December 5, 2023 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...
Press Release
September 5, 2023
SOUTH SAN FRANCISCO, CA, September 5, 2023 – Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics...
Press Release
May 23, 2023
SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...
Press Release
April 6, 2023
Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...
Press Release
December 6, 2022
With $40 million in financing to date, company has advanced lead drug candidate, VGA039, to clinical stage to treat von Willebrand disease...
Press Release
February 16, 2022
Drug discovery approach uncovers novel biology for treatments that can target multiple diseases with a single therapy. Star Therapeutics has formed a...
Press Release
News Coverage
- Jennifer Boggs, BioWorld
- September 5, 2023
Star Therapeutics Inc. brought on board six new investors in its oversubscribed $90 million series C round, raising the company’s total funding to more than $190 million since its founding in 2018 to advance in-house drug discovery efforts via formation of portfolio companies. Since emerging from stealth in early...
- Kyle LaHucik, Endpoints
- September 5, 2023
Star Therapeutics, which created two antibody-focused biotech startups with more in the works, has now reeled in a $90 million Series C. The round, disclosed Tuesday morning, brings the Bay Area biotech’s total financing to more than $190 million since emerging from Westlake Village BioPartners in early 2022. Star’s biotech startups Vega Therapeutics and Electra Therapeutics...
- Gabrielle Masson, FIERCE Biotech
- September 5, 2023
Investors have showered Star Therapeutics with $90 million to grow its portfolio companies and develop new antibody drugs for diseases with high unmet need. Sofinnova Investments led the oversubscribed series C round and was joined by new investors Qatar Investment Authority, Catalio Capital Management, Agent Capital, Soleus Capital and NYBC Ventures alongside all seven...
- By Damian Doherty, Inside Precision Medicine
- December 23, 2022
Adam Rosenthal is the CEO and founder of Star Therapeutics, a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible. The company’s engine for innovation starts with identifying multiple rare diseases that share a common biology and then discovering novel therapeutics that can treat these diseases with a single therapy. Star consists…
